

**Clinical trial results:**  
**Remission Induction by Etanercept in Enthesitis related Arthritis JIA-  
Patients (juvenile undifferentiated Spondylarthropathy)****Summary**

EudraCT number	2010-020423-51
Trial protocol	DE
Global end of trial date	22 September 2014

**Results information**

Result version number	v1 (current)
This version publication date	26 November 2021
First version publication date	26 November 2021
Summary attachment (see zip file)	Efficacy and Safety of Etanercept in Patients with ERA-JIA (Results_2010-020423-51.pdf)

**Trial information****Trial identification**

Sponsor protocol code	ETA0881X1-4718
-----------------------	----------------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Asklepios Klinik
Sponsor organisation address	Arnold Janssen Str., Sankt Augustin, Germany,
Public contact	Asklepios Klinik Sankt Augustin, Asklepios Klinik Sankt Augustin, +49 2241249200, g.horneff@asklepios.com
Scientific contact	Asklepios Klinik Sankt Augustin, Asklepios Klinik Sankt Augustin, +49 2241249200, g.horneff@asklepios.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 April 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 September 2014
Global end of trial reached?	Yes
Global end of trial date	22 September 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

This study is intended to generate first evidence that treatment with etanercept is safe and effective in patients diagnosed with ERA-JIA who are able to acquire stable remission (inactive disease).

Protection of trial subjects:

No additional visits apart from normal clinical Routine wer requested. No additional Blood test apart from test usually performed for Routine clinical care were required.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 March 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 41
Worldwide total number of subjects	41
EEA total number of subjects	41

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	9
Adolescents (12-17 years)	32
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Recruitment started in May 2011 in 8 sites in Germany

### Pre-assignment

Screening details:

Key inclusion criteria consisted of: 1) diagnosis of ERA JIA as determined by the International League of Associations for Rheumatology 2) active disease 3) age 6 to <18 years at baseline 4) inadequate response or intolerance to at least one NSAID and at least one DMARD, either SSZ or MTX 5) currently being treated with a DMARD or, if the patient

### Period 1

Period 1 title	open phase
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	open phase
Arm description: -	
Arm type	open phase
Investigational medicinal product name	etanercept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

subcutaneous administration of 0.8mg /kg body weight once per week, maximum 50mg /week

<b>Number of subjects in period 1</b>	open phase
Started	41
Completed	39
Not completed	2
Adverse event, non-fatal	1
Protocol deviation	1

### Period 2

Period 2 title	placebo-controlled phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer

---

**Arms**

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Verum
------------------	-------

Arm description: -

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	etanercept
--	------------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Solution for solution for injection
----------------------	-------------------------------------

Routes of administration	Subcutaneous use
--------------------------	------------------

Dosage and administration details:

subcutaneous administration of 0.8mg /kg body weight once per week, maximum 50mg /week

<b>Arm title</b>	Placebo
------------------	---------

Arm description: -

Arm type	Placebo
----------	---------

Investigational medicinal product name	placebo
--	---------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Solution for injection
----------------------	------------------------

Routes of administration	Subcutaneous use
--------------------------	------------------

Dosage and administration details:

placebo applied subcutaneoulsy once per week

<b>Number of subjects in period 2<sup>[1]</sup></b>	Verum	Placebo
Started	20	18
Completed	20	18

---

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: One patient was not randomized as the patient did not meet the required ACR30 criteria to continue in the randomized phase.

## Baseline characteristics

### Reporting groups

Reporting group title	open phase
-----------------------	------------

Reporting group description: -

Reporting group values	open phase	Total	
Number of subjects	41	41	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	9	9	
Adolescents (12-17 years)	32	32	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	13.44		
standard deviation	± 2.5	-	
Gender categorical			
Units: Subjects			
Female	12	12	
Male	29	29	

### Subject analysis sets

Subject analysis set title	Placebo controlled
----------------------------	--------------------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

2 arms (Placebo and verum)

Reporting group values	Placebo controlled		
Number of subjects	38		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	9		
Adolescents (12-17 years)	29		
Adults (18-64 years)	0		

From 65-84 years	0		
85 years and over	0		

Age continuous			
Units: years			
arithmetic mean	13.3		
standard deviation	± 2.5		
Gender categorical			
Units: Subjects			
Female			
Male			

## End points

### End points reporting groups

Reporting group title	open phase
Reporting group description: -	
Reporting group title	Verum
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	
Subject analysis set title	Placebo controlled
Subject analysis set type	Intention-to-treat
Subject analysis set description: 2 arms (Placebo and verum)	

### Primary: remission under treatment with Etanercept

End point title	remission under treatment with Etanercept <sup>[1]</sup>
End point description: Primary endpoint Phase 1: To assess the clinical benefit (remission) of etanercept in subjects with ERA-JIA. Phase 2: To assess the stability of drug free remission reached upon treatment with etanercept.	
End point type	Primary
End point timeframe: baseline till week 48	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: One arm in this phase. End point is reported descriptive.

End point values	open phase			
Subject group type	Reporting group			
Number of subjects analysed	39			
Units: patients	23			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Flare

End point title	Flare
End point description:	
End point type	Secondary
End point timeframe: 24-48 week	

<b>End point values</b>	open phase	Placebo controlled		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	38	38		
Units: Patients with flare				
Placebo	18	9		
verum	20	3		

## Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

0-48 weeks

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.1
--------------------	------

### Reporting groups

Reporting group title	All-exposure safety group
-----------------------	---------------------------

Reporting group description: -

<b>Serious adverse events</b>	All-exposure safety group		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 41 (4.88%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
Fracture			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal hemorrhage			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	All-exposure safety group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	37 / 41 (90.24%)		
Nervous system disorders			

Headache subjects affected / exposed occurrences (all)	6 / 41 (14.63%) 7		
General disorders and administration site conditions Adverse drug reaction subjects affected / exposed occurrences (all)  Fatigue subjects affected / exposed occurrences (all)  Fever subjects affected / exposed occurrences (all)	12 / 41 (29.27%) 19  3 / 41 (7.32%) 4  2 / 41 (4.88%) 3		
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)  Diarrhea subjects affected / exposed occurrences (all)	6 / 41 (14.63%) 7  3 / 41 (7.32%) 3		
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)  knee pain subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 6  1 / 41 (2.44%) 3		
Infections and infestations Gastrointestinal infection subjects affected / exposed occurrences (all)  Bronchitis subjects affected / exposed occurrences (all)  Upper respiratory tract infection	Additional description: 16 14 / 41 (34.15%) 16  2 / 41 (4.88%) 3		

subjects affected / exposed	16 / 41 (39.02%)		
occurrences (all)	25		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

small number of patients available for study enrollment, which could be attributed to the rarity of the disease; however, the number of patients was sufficiently high to evaluate the primary outcome criteria.

Notes:

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/25891010>